Welcome to our dedicated page for Poseida Therapeutics news (Ticker: PSTX), a resource for investors and traders seeking the latest updates and insights on Poseida Therapeutics stock.
Poseida Therapeutics, Inc. (Nasdaq: PSTX) is a clinical-stage biopharmaceutical company that specializes in developing innovative cell and gene therapies aimed at curing certain cancers and rare diseases. The company's core focus is on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with unmet medical needs. Poseida's pipeline includes autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates, initially targeting hematological malignancies and solid tumors.
Poseida boasts best-in-class genome engineering capabilities, utilizing proprietary tools like the piggyBac™ DNA modification system, nextGEN™ CRISPR, XTN™ TALEN, and the footprint-free™ gene editing system. These tools are virus-free and offer surgical precision in gene editing, enabling the development of highly effective therapies.
Recent achievements include significant advancements in the company's lead program, P-BCMA-ALLO1, a novel BCMA-targeted allogeneic CAR-T therapy for treating relapsed/refractory multiple myeloma (RRMM). The FDA recently granted Orphan Drug Designation for P-BCMA-ALLO1, underscoring its potential to meet high unmet medical needs. Poseida is investigating this therapy in collaboration with Roche, with promising preliminary data presented at major scientific conferences.
In addition to its focus on cancer, Poseida is also advancing genetic medicines for rare diseases. The company has highlighted progress in its gene therapy pipeline, especially for conditions like Hereditary Angioedema and Hemophilia A. These programs employ fully non-viral approaches, leveraging Poseida's advanced genetic engineering and delivery platforms.
Poseida has formed strategic collaborations with industry giants like Janssen and Roche, enhancing its capacity to bring innovative therapies to market. The company also recently entered into a research collaboration with Xyphos Biosciences, a subsidiary of Astellas, to develop novel convertibleCAR® programs targeting solid tumors.
Financially, Poseida reported revenues of $28.1 million for Q1 2024, a substantial increase from the previous year, primarily driven by collaborations with Astellas and Roche. With a strong cash position and additional funding from strategic partnerships, Poseida is well-positioned to advance its pipeline and achieve key milestones in 2024 and beyond.
Learn more about Poseida Therapeutics and its groundbreaking work by visiting www.poseida.com and connecting with the company on X and LinkedIn.
Poseida Therapeutics (PSTX) announced a peer-reviewed publication validating its Cas-CLOVER Site-specific Gene Editing System for producing allogeneic CAR-T cells. The research demonstrates that Cas-CLOVER achieves a high percentage (45%-70%) of T stem cell memory (Tscm) cells with significantly lower off-target activity (0.012%-0.089%) compared to other technologies like CRISPR. This advancement may enhance clinical responses and tolerability in cancer treatments. The publication appears in the September 2022 issue of Molecular Therapy – Nucleic Acids.
Poseida Therapeutics (Nasdaq: PSTX) will hold its virtual Annual Meeting of Stockholders on June 16, 2022, at 1:00 p.m. PT. Stockholders recorded as of April 20, 2022, can participate in the meeting via a live webcast. An online portal is available for stockholders to view proxy materials and vote shares in advance. Registration is required by June 14, 2022, and the meeting's website opens at 12:45 p.m. PT on the meeting day. Poseida focuses on creating innovative gene and cell therapeutics using proprietary technologies.
Poseida Therapeutics presented promising preclinical data on P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting, showcasing its potential as a safer preconditioning agent for hematopoietic stem cell (HSC) transplants. The data indicates that P-ckit-ALLO1 effectively eliminates over 95% of HSPCs and enhances survival in acute myeloid leukemia (AML) models. Utilizing advanced genetic technologies, P-ckit-ALLO1 could serve dual purposes: improving HSC transplant outcomes and acting as an anti-tumor therapy, presenting a less toxic alternative compared to existing treatments.
Poseida Therapeutics (Nasdaq: PSTX) announced its Q1 2022 financial results, reporting revenues of $1.4 million, up from $0 in Q1 2021, attributed to a collaboration with Takeda. However, net loss increased to $58.1 million compared to $38.3 million in 2021. R&D expenses rose to $48.9 million due to increased clinical activities and manufacturing capacity reductions. The company's cash position stands at $183.5 million. Poseida is advancing multiple CAR-T and gene therapy programs, with plans for clinical data updates later in 2022.
Poseida Therapeutics (Nasdaq: PSTX) announced that it will present preclinical data on its anti-c-kit CAR-T cell therapy, P-ckit-ALLO1, at the ASGCT 25th Annual Meeting in Washington, D.C., from May 16-19, 2022. This therapy aims to improve hematopoietic stem cell transplants by demonstrating a specific, less toxic conditioning regimen. The research highlights the potential for treating acute myeloid leukemia (AML) and enhancing HSC engraftment. The poster presentation is scheduled for May 17, 2022, at 5:30 PM ET.
Poseida Therapeutics, Inc. (Nasdaq: PSTX) announced that CEO Mark Gergen will present at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 2:40pm PT in Las Vegas. The live presentation can be accessed via a webcast on Poseida's website, with a replay available for 30 days post-event. Poseida is focused on developing innovative cell and gene therapeutics using proprietary technologies like the non-viral piggyBac® DNA Delivery System and Cas-CLOVER™ gene editing, aimed at addressing limitations in current therapies.
Poseida Therapeutics (PSTX) reported Q4 and full-year 2021 financials, showcasing $31.2 million in revenue from a collaboration with Takeda, a significant increase from zero revenue in 2020. R&D expenses rose to $39.1 million for Q4, up from $27.9 million year-over-year, contributing to a net income of $1.5 million compared to a net loss of $36.1 million in Q4 2020. As of December 31, 2021, cash reserves were $206.3 million. Key developments include IND clearance for P-MUC1C-ALLO1 and initial clinical data expected in H2 2022.
Poseida Therapeutics (PSTX) announced an inducement award to Brent Warner, its new President of Gene Therapy, as part of its 2022 Inducement Plan. The award includes a stock option for 431,034 shares, with a vesting schedule over four years, and a restricted stock unit covering 307,881 shares with similar vesting terms. The exercise price of the stock option will equal the market value on the grant date. This move is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to attract and retain key talent within the company.
Poseida Therapeutics (NASDAQ: PSTX) hosted its second annual virtual R&D Day on February 23, 2022, showcasing advancements in its clinical and preclinical pipeline. The event highlighted the company's innovative genetic engineering technologies, including site-specific transposon-based DNA delivery, which could transform gene therapy. Presentations included updates on CAR-T therapy programs and liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101. Poseida emphasized its commitment to addressing significant medical needs through its proprietary platforms and technologies.
Poseida Therapeutics (NASDAQ: PSTX) announced the appointment of Brent Warner as President, Gene Therapy, effective February 21, 2022. Warner brings over 15 years of experience in the biotech sector, previously holding senior roles at Novartis and BioMarin. His expertise will drive the company’s gene therapy programs, particularly a recent collaboration with Takeda. CEO Mark Gergen expressed optimism about Warner's leadership, aligning with Poseida's mission to advance innovative gene therapies for rare diseases.
FAQ
What is the current stock price of Poseida Therapeutics (PSTX)?
What is the market cap of Poseida Therapeutics (PSTX)?
What is Poseida Therapeutics, Inc.?
What are Poseida's core technologies?
What is P-BCMA-ALLO1?
Who are Poseida's strategic partners?
What diseases is Poseida targeting with its gene therapies?
What recent financial achievements has Poseida reported?
What is Poseida's approach to gene editing?
How can I learn more about Poseida Therapeutics?
What is the significance of the Orphan Drug Designation for P-BCMA-ALLO1?
What are Poseida's future plans?
